Eledon Pharmaceuticals (ELDN) Change in Accured Expenses (2013 - 2022)

Eledon Pharmaceuticals (ELDN) has 10 years of Change in Accured Expenses data on file, last reported at $210000.0 in Q4 2022.

• Quarterly Change in Accured Expenses rose 28.83% year-over-year to $210000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $2.1 million (down 2.89% YoY) and the FY2022 annual result came in at $2.1 million, down 2.89% from the prior year.
• Change in Accured Expenses slipped to $210000.0 in Q4 2022, from $2.9 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.2 million in Q3 2020 to a low of -$4.0 million in Q4 2020.
• A 5-year average of $194350.0 and a median of $171000.0 in 2018 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 1558.42% in 2020, down 1084.21% in 2020.
• Tracing ELDN's Change in Accured Expenses over 5 years: stood at $931000.0 in 2018, then slumped by 136.73% to -$342000.0 in 2019, then tumbled by 1084.21% to -$4.0 million in 2020, then soared by 104.02% to $163000.0 in 2021, then grew by 28.83% to $210000.0 in 2022.
• The last three Change in Accured Expenses figures came in at $210000.0 (Q4 2022), $2.9 million (Q3 2022), and $359000.0 (Q2 2022), per Business Quant data.